Pulmonary administration of chemically modified insulin
AssigneeNektar Therapeutics
InventorsJohn S. Patton, Mei-Chang Kuo, J. Milton Harris, Chester Leach, Kimberly Perkins, Blaine Bueche
Life of this patent
Estimating the term…
Abstract
The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
Claims77
An insulin composition for pulmonary administration, said composition comprising a conjugate of insulin covalently coupled to one or more molecules of a non-naturally occurring hydrophilic polymer.
A method for providing a substantially non-immunogenic insulin composition for administration to the lung of a subject in need thereof, said method comprising:
- covalently coupling insulin to one or more molecules of a non-naturally occurring hydrophilic polymer to provide a composition comprising an insulin-hydrophilic polymer conjugate, and
- administering said composition to the lung of a subject in need thereof by inhalation, whereby as a result of said administering, said insulin passes through the lung and enters into the blood circulation.
A method for providing a prolonged-effect insulin composition for administration to the lung of a subject in need thereof, said method comprising:
- covalently coupling insulin to one or more molecules of a non-naturally occurring hydrophilic polymer to provide a composition comprising an insulin-hydrophilic polymer conjugate,
- administering said composition to the lung of a subject in need thereof by inhalation, whereby as a result of said administering, (i) said insulin passes through the lung and enters the blood circulation, and (ii) elevated blood levels of insulin are sustained for at least 8 hours post administration.
Dependencies are inferred from the claim text.